DNTH

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for the treatment of severe autoimmune diseases. The Company's lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (C1s) - enabling less frequent and convenient self-administered subcutaneous (S.C.) injections suitable for a pre-filled pen. It is conducting three mid- to late-stage clinical trials with claseprubart in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The Company's second clinical-stage candidate, DNTH212, is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.